| |
| Frequently Asked Questions |
| |
What is the focus of Carl Zeiss Meditec AG’s business activities?
What are the cornerstones of the Carl Zeiss Meditec strategy?
Which are the main products of Carl Zeiss Meditec AG?
How many people does Carl Zeiss Meditec AG employ? What is the regional presence of Carl Zeiss Meditec AG?
What is the shareholding structure in Carl Zeiss Meditec AG?
What is the shareholding structure of the scattered holdings?
How many Carl Zeiss Meditec shares are outstanding?
At which stock exchanges are Carl Zeiss Meditec shares traded? What are its securities identification numbers?
In which indices are Carl Zeiss Meditec shares represented?
Where can I obtain information on the price movement of Carl Zeiss Meditec shares?
What were the last dividend payments and when were they distributed?
When is the next scheduled AGM?
How and where can a shareholder register for the AGM?
What is the focus of Carl Zeiss Meditec AG's business activities?
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials.
The company creates innovative visualisation solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy.
In the 2009/2010 (30 September) financial year the approx. 2,200 employees generated revenue of approximately € 676 million. The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France.
Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". The head office of Carl Zeiss AG is in Oberkochen, Germany. In financial year 2009/2010 (balance sheet date: 30 September) the Group generated revenue of around € 3.0 billion. Carl Zeiss employs almost 13,000 staff, over 8,000 thereof in Germany.
Top
What are the cornerstones of the Carl Zeiss Meditec strategy?
In spite of the difficult global economic climate, we are seeing a growth in demand for our diagnostic and therapeutic products, due to fundamental trends, such as a continuously aging global population. This applies to both ophthalmology and microsurgery and assures us that the good selling conditions for our products will continue.
We also consider ourselves to be in a good position, due to our company programme RACE 2010, which we have consistently implemented since 2009. The further development of the Group shall thus also be based in the coming years on the five strategic priorities defined in 2008:
- Acceleration and efficiency in innovation
- Entry into new markets
- Customer focus in sales and service
- Process excellence in all areas
- Employee development and support.
Innovation
Three comprehensive solutions (ZEISS Toric Solution, ZEISS Data Management and ZEISS Refractive Laser Solution) were launched during the financial year under review and were met with enthusiasm from our customers.
New markets
The phaco system VisalisTM 100 launched in the financial year under review is a system that is specifically tailored to the needs of physicians in growth markets. For the first time, we chose a growth market, India, to present a new innovation. This system further expands our extensive range of innovative solutions for ophthalmic surgery.
We shall continue to expand into the markets of the coming decades in future, too.
Customer focus
The global service business is one of the areas that offer us massive opportunities for growth. We still see a lot of untapped potential here, as well as a need to further consolidate this area. In future, therefore, we plan to push forward with the standardisation and streamlining of the most important customer care processes and create an organisational platform to continue providing successful services, and thus improve the satisfaction of our customers.
Process excellence
The alignment of the first key processes with uniform, Group-wide standards began in 2008/2009. The aim now is to drive these cross-departmental approaches faster forward and thus become more efficient as an organisation overall.
Employees
Forward-looking human resources policy focuses on sustainable development and targeted support of the potential of all employees. A particular focus is on the development of the skills of young talent, for which we set up a mentoring programme in 2009. The trusting, personal exchange with experienced members of staff offers not only the exchange of specialised knowledge, but also support in overcoming new challenges and complex work situations, and professional career planning.
Top
Which are the main products of Carl Zeiss Meditec AG?
Carl Zeiss Meditec has an extensive and innovative portfolio of products for the diagnosis and treatment of major eye ailments. These include:
- The Cirrus™ HD-OCT is a optical coherence tomography system which provides unique views of retina based on precise segmenting algorithms and high quality 3D images (for example, early diagnosis of glaucoma and retinal disorders)
- The IOLMASTER® for accurate and efficient non-contact measurement of the eye prior to a cataract operation
- The Humphrey® Field Analyzer for static and kinetic measurement of the visual field in support of glaucoma diagnosis
- The new Femtosecondlaser VisuMax® sets standards with precise beam guidance and a balanced relationship of repetition rate and laser pulse energy for accurate and gentle treatment of eye
- VISUCAM™ PRO NM fundus camera for accurate examination of the fundus of the eye without the use of mydriatric pharmaceuticals (for widening the pupils)
- The surgical microscope OPMI Lumera® for ophthalmology with stereo coaxal illumination which enables a successful combination of red reflex and with excellent contrast which is used to illuminate the anterior eye segments from the rear
- AT.Lisa, is the world’s first real multifocal micro-incision (MICS) lens for presbyopia correction with a micro-incision size of up to 1.5 mm.
Top
How many people does Carl Zeiss Meditec AG employ? What is the regional presence of Carl Zeiss Meditec AG?
Carl Zeiss Meditec employs over 2,300 people worldwide. Over 350 of them staff the head office of Carl Zeiss Meditec AG in Jena.
Carl Zeiss Meditec is directly represented in USA, Japan, Germany, Spain and France with its own subsidiaries in these countries. In other countries the company makes use of the powerful and well-focused distribution network of Carl Zeiss AG.
Top
What is the shareholding structure in Carl Zeiss Meditec AG?
65% of the shares are held by Carl Zeiss AG, the remaining 35% are held by freefloat investors.
With the exception of Carl Zeiss AG, no shareholder holds more than 5% of Carl Zeiss Meditec shares.
What is the shareholding structure of the scattered holdings?
About 70% of the scattered holdings are held by institutional investors, the remaining 30% by private investors.
How many Carl Zeiss Meditec shares are outstanding?
Currently 81,309,610 Carl Zeiss Meditec AG shares are outstanding.
At which stock exchanges are Carl Zeiss Meditec shares traded? What are its securities identification numbers?
Carl Zeiss Meditec shares are traded at the Deutsche Börse in Frankfurt (XETRA and on the floor, “Parkett”) as well as at regional stock exchanges in Berlin, Bremen, Düsseldorf, Hamburg, Munich and Stuttgart.
| Stock exchange abbreviation: | AFX |
| ISIN: | DE0005313704 |
| RIC ( Reuters Identification Code): | AFXG.F (floor, "Parkett")
AFXG.DE (XETRA) |
| Bloomberg: | AFX GR |
Top
In which indices are Carl Zeiss Meditec shares represented?
Carl Zeiss Meditec shares are represented in TecDAX, CDAX, DAX International Mid 100, DAXsector All Pharma & Healthcare, DAXsector Pharma & Healthcare, DAXsubsector All Medical Technology, DAXsubsector Medical Technology, Prime All Share, Technology All Share, DAXglobal Sarasin Sustainability German Index, MIDCAP MKT P-IN and HDAX.
Where can I obtain information on the price movement of Carl Zeiss Meditec shares?
You will find current and historic price information at our Website under "Shares" and those of other providers.
What were the last dividend payments and when were they distributed?
By shareholders' resolution at the Annual General Meeting of 12 April 2011 Carl Zeiss Meditec paid a dividend of € 0.22 for financial year 2009/2010. In addition, a special dividend of € 0.33 was paid per no-par value share. The payout date was 13 April 2011. The day on which our shares were traded ex dividend was 13 April 2011.
Top
When is the next scheduled AGM?
The Annual General Meeting 2012 take place on March 9th in Weimar.
How and where can a shareholder register for the AGM?
About four weeks prior to the appointed date, shareholders will receive an invitation to the AGM, together with the agenda, through their custodian banks. Shareholders can use the corresponding reply form either to request an admission ticket or to issue a proxy authorisation to the bank. Further formal information can be found in the section “Annual General Meeting” in the current Articles of Association of Carl Zeiss Meditec AG.
In addition, Carl Zeiss Meditec acknowledges the recommendations of the German Corporate Government Codex for the support of shareholders in exercising their right to vote. Accordingly, shareholders may also authorise the company’s proxies to represent them. Further details will be included on the respective invitation to the AGM as soon as it has been issued.
top | |  |